Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2010 Financial Results

Conference Call and Webcast Thursday, July 29, 2010

SAN DIEGO, July 22 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its second quarter 2010 financial results after the Nasdaq market closes on Wednesday, July 28, 2010.  Neurocrine will then host a  live conference call and webcast to discuss its financial results and provide a Company update Thursday morning, July 29, 2010 at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time).

Participants can access the live conference call by dialing 1-800-894-5910, (US) or 785-424-1052 (International) using the conference ID: 7NBIX. The call can also be accessed via the webcast through the Company's website at http://www.neurocrine.com.  If you are unable to attend the webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600.  A replay of the Conference Call will be available approximately one hour after the conclusion of the call by dialing 1-800-753-5207 (US) or 402-220-2156 (International) using the conference ID: 7NBIX. The call will be archived for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

SOURCE Neurocrine Biosciences, Inc.

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.